Phenotyping the virulence of SARS-CoV-2 variants in hamsters by digital pathology and machine learning
Gavin R Meehan,Vanessa Herder,Jay Allan,Xinyi Huang,Karen Kerr,Diogo Correa Mendonca,Georgios Ilia,Derek W Wright,Kyriaki Nomikou,Quan Gu,Sergi Molina Arias,Florian Hansmann,Alexandros Hardas,Charalampos Attipa,Giuditta De Lorenzo,Vanessa Cowton,Nicole Upfold,Natasha Palmalux,Jonathan C Brown,Wendy S Barclay,Ana Da Silva Filipe,Wilhelm Furnon,Arvind H Patel,Massimo Palmarini,Gavin R. Meehan,Derek W. Wright,Jonathan C. Brown,Wendy S. Barclay,Arvind H. Patel
DOI: https://doi.org/10.1371/journal.ppat.1011589
IF: 7.464
2023-11-08
PLoS Pathogens
Abstract:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continued to evolve throughout the coronavirus disease-19 (COVID-19) pandemic, giving rise to multiple variants of concern (VOCs) with different biological properties. As the pandemic progresses, it will be essential to test in near real time the potential of any new emerging variant to cause severe disease. BA.1 (Omicron) was shown to be attenuated compared to the previous VOCs like Delta, but it is possible that newly emerging variants may regain a virulent phenotype. Hamsters have been proven to be an exceedingly good model for SARS-CoV-2 pathogenesis. Here, we aimed to develop robust quantitative pipelines to assess the virulence of SARS-CoV-2 variants in hamsters. We used various approaches including RNAseq, RNA in situ hybridization, immunohistochemistry, and digital pathology, including software assisted whole section imaging and downstream automatic analyses enhanced by machine learning, to develop methods to assess and quantify virus-induced pulmonary lesions in an unbiased manner. Initially, we used Delta and Omicron to develop our experimental pipelines. We then assessed the virulence of recent Omicron sub-lineages including BA.5, XBB, BQ.1.18, BA.2, BA.2.75 and EG.5.1. We show that in experimentally infected hamsters, accurate quantification of alveolar epithelial hyperplasia and macrophage infiltrates represent robust markers for assessing the extent of virus-induced pulmonary pathology, and hence virus virulence. In addition, using these pipelines, we could reveal how some Omicron sub-lineages (e.g., BA.2.75 and EG.5.1) have regained virulence compared to the original BA.1. Finally, to maximise the utility of the digital pathology pipelines reported in our study, we developed an online repository containing representative whole organ histopathology sections that can be visualised at variable magnifications (https://covid-atlas.cvr.gla.ac.uk). Overall, this pipeline can provide unbiased and invaluable data for rapidly assessing newly emerging variants and their potential to cause severe disease. New SARS-CoV-2 variants have periodically emerged throughout the COVID-19 pandemic. The key characteristic possessed by "successful" variants in this phase of the pandemic is their ability to evade the immunity conferred by existing SARS-CoV-2 vaccines or infections. However, it is not clear whether new variants will maintain the relatively low virulence shown by Omicron or acquire the more virulent phenotype of the pre-omicron variants. In this study, we developed software-assisted image analysis methods to quantitatively assess the extent of the lesions in lungs of hamsters experimentally infected with SARS-CoV-2. Hamsters are an excellent animal model to assess SARS-CoV-2 virulence. Based on previous experiments, we reasoned that the virulence of SARS-CoV-2 variants will be directly proportional to the lung lesions they cause in hamsters. We developed unbiased methods aimed to image whole lung sections, and quantify immune cells infiltrating the organ, in addition to the levels of lung cells proliferation in response to virus injury. Using these methods, we show that Omicron is, as expected, less virulent than the Delta variant. The virulence of other variants such as XBB and BQ.1.18 is comparable to that displayed by Omicron. However, the more recently emerged variants BA.2.75 and EG.5.1 are more virulent than Omicron, but not Delta. Our methods can provide a quantitative assessment of the ability of newly emerging variants to cause severe disease.
microbiology,virology,parasitology